I'm suggesting that there are many potential possibilities to partner, even K as an adjuvant, this is not an all or nothing pivot point as many are implying. I suspect the future may be some combination that is difficult to predict at this moment. This company will not go out of business with all of the potential that their three platform drugs afford.